ADG-106
ADG-106 is a fully human agonistic monoclonal IgG4 antibody against CD137 (4-1BB). ADG-106 has the mechanism to activate CD137 via strong FcγRIIB-mediated crosslinking while antagonizing CD137 ligands. The isotype control for ADG-106 can refer to Human IgG4 (S228P) kappa, Isotype Control.
Product Specifications
UNSPSC
12352203
Target
TNF Receptor
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
[ADG-106]
References & Citations
[1]Ma Y, et al. Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin's lymphoma. Cell Rep Med. 2024 Feb 20;5 (2) :101414.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
More Discoveries
Explore Other Products
Browse additional items from our catalog
